Imyun Pharma
Modular Protein Conjugates that Redirect Memory T Cells to Kill Targeted Disease Cells
Company Overview
Snapshot
Founded in May 2026 by Leon Boston and Lior Carmon, Imyun Pharma operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on developing its innovative Immune-Tag Conjugates (ITC™) platform.
Business overview
Imyun Pharma is a biotechnology company developing Immune-Tag Conjugates (ITC™), a modular recombinant protein platform designed to leverage existing immune memory for clearing targeted disease cells. This mechanism involves an antibody domain that binds to specific surface markers on pathological cells, delivering a pathogen-derived signal peptide internally. Once processed, this peptide is presented on MHC Class I molecules, directing existing pathogen-primed CD8+ memory T cells to destroy the target cell. The platform's modularity allows for redirection across various oncology, autoimmune, and inflammatory indications, with its lead preclinical asset, ORION™, currently targeting HER2+ solid tumors. The company operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Biomaterials & Tissue Engineering, serving the Healthcare & Life Sciences market in North America.
Log in to access full profile ›Company Intelligence Q&A
- What is Imyun Pharma's core technology?
- Imyun Pharma develops Immune-Tag Conjugates (ITC™), a modular recombinant protein platform that redirects existing immune memory to eliminate targeted disease cells.
- Which markets does Imyun Pharma target?
- Imyun Pharma targets the Healthcare & Life Sciences market, with a primary focus on North America.
- Who are the founders of Imyun Pharma?
- Imyun Pharma was founded by Leon Boston, who serves as Co-founder & CEO, and Lior Carmon, the Co-founder & CSO.
- What is the current development stage of Imyun Pharma's lead asset?
- Imyun Pharma's lead preclinical asset, ORION™, is currently in the preclinical stage and is designed to target HER2+ solid tumors.
- What is the primary application of Imyun Pharma's platform?
- Imyun Pharma's platform can be redirected across various oncology, autoimmune, and inflammatory indications by swapping targeting modules.